Explore the expanding treatment options for EGFR mutated metastatic non-small cell lung cancer. Key topics include the role of biomarkers in treatment decisions, FDA-approved targeted therapies, and the necessity of comprehensive testing. A case study illustrates the diagnostic process leading to the identification of an EGFR Exon 19 deletion. The session emphasizes the importance of tailored treatment approaches and collaboration among healthcare professionals to improve patient outcomes.